Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CLRB Stock Summary
Top 10 Correlated ETFs
CLRB
In the News
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
Cellectar Biosciences to Present at the 36th Annual Roth Conference
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are as follows:
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval. The company has a strong chance at approval but faces cash concerns and the challenge of a small market size for its drug.
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation are as follows:
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the company, iopofosine I 131 performed well in the trial as a potential first-in-class, targeted radiotherapy candidate to treat patients with relapsed/refractory Waldenstrom's macroglobulinemia that have already undergone a minimum of two previous forms of therapy.
Cellectar's blood cancer therapy succeeds in trial
Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar's chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical Conference Call Participants Jonathan Aschoff - ROTH MKM Jeffrey Jones - Oppenheimer Ahu Demir - Ladenburg Jason McCarthy - Maxim Group Operator Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.
Here's Why Cellectar Biosciences Shares Are Rising
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.
CLRB Financial details
CLRB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -44.7 | -18.08 | -7.45 | -4.32 | -4.05 | |
Operating cash flow per share | -38.63 | -15.24 | -7.03 | -4.07 | -3.57 | |
Free cash flow per share | -39.93 | -15.27 | -7.06 | -4.09 | -3.61 | |
Cash per share | 44.75 | 13.83 | 28.85 | 6.43 | 2.82 | |
Book value per share | 44.77 | 11.8 | 27.66 | 5.95 | 2.2 | |
Tangible book value per share | 44.77 | 11.8 | 27.66 | 5.95 | 2.2 | |
Share holders equity per share | 44.77 | 11.8 | 27.66 | 5.95 | 2.2 | |
Interest debt per share | 0.11 | 0.69 | 0.21 | 0.05 | 0.04 | |
Market cap | 4.59M | 17.27M | 41.21M | 36.64M | 12.07M | |
Enterprise value | -8.66M | 7.18M | -15.53M | 1.24M | -7.2M | |
P/E ratio | -0.35 | -1.24 | -2.79 | -1.53 | -0.42 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.4 | -1.48 | -2.96 | -1.62 | -0.48 | |
PFCF ratio | -0.39 | -1.47 | -2.94 | -1.61 | -0.47 | |
P/B Ratio | 0.35 | 1.91 | 0.75 | 1.11 | 0.78 | |
PTB ratio | 0.35 | 1.91 | 0.75 | 1.11 | 0.78 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.87 | -0.5 | 1 | -0.05 | 0.25 | |
EV to operating cash flow | 0.76 | -0.61 | 1.11 | -0.05 | 0.29 | |
EV to free cash flow | 0.73 | -0.61 | 1.11 | -0.05 | 0.28 | |
Earnings yield | -2.88 | -0.8 | -0.36 | -0.65 | -2.37 | |
Free cash flow yield | -2.58 | -0.68 | -0.34 | -0.62 | -2.11 | |
Debt to equity | 0 | 0.06 | 0.01 | 0.01 | 0.04 | |
Debt to assets | 0 | 0.04 | 0.01 | 0.01 | 0.03 | |
Net debt to EBITDA | 1.33 | 0.71 | 3.67 | 1.47 | 0.67 | |
Current ratio | 8.6 | 4.11 | 16.26 | 9.16 | 3.71 | |
Interest coverage | -449.04 | 0 | 0 | 0 | 95.74 | |
Income quality | 0.86 | 0.83 | 0.92 | 0.94 | 0.88 | |
Dividend Yield | 0.49 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.17 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0 | 0 | 0.01 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -4.68 | -0.18 | -0.44 | -0.94 | -1.52 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 212.19 | 69.29 | 68.08 | 24.05 | 14.16 | |
ROIC | -0.89 | -1.38 | -0.27 | -0.71 | -1.72 | |
Return on tangible assets | -0.88 | -1.13 | -0.25 | -0.64 | -1.32 | |
Graham Net | 38.7 | 9.67 | 26.9 | 5.68 | 1.95 | |
Working capital | 12.33M | 8.62M | 54.38M | 32.58M | 15M | |
Tangible asset value | 13.26M | 9.06M | 54.79M | 33.05M | 15.51M | |
Net current asset value | 12.16M | 8.19M | 54.07M | 32.41M | 14.45M | |
Invested capital | 0 | 0.06 | 0.01 | 0.01 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 306K | 945K | 1.35M | 1.42M | 1.99M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 2.46K | 2.51K | 2.27K | 3.91K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.15 | 0.15 | 0.16 | 0.09 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1 | -1.53 | -0.27 | -0.73 | -1.84 | |
Capex per share | -1.3 | -0.03 | -0.03 | -0.03 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.28 | -1.02 | -0.75 | -0.73 | -1.21 | |
Operating cash flow per share | -1.15 | -1.05 | -0.64 | -0.67 | -0.71 | |
Free cash flow per share | -1.15 | -1.07 | -0.64 | -0.67 | -0.77 | |
Cash per share | 2.91 | 2.82 | 1.13 | 0.46 | 1.68 | |
Book value per share | 2.09 | 2.2 | 0.65 | -0.04 | -1.18 | |
Tangible book value per share | 2.09 | 2.2 | 0.65 | -0.04 | -1.18 | |
Share holders equity per share | 2.09 | 2.2 | 0.65 | -0.04 | -1.18 | |
Interest debt per share | 0.03 | 0.08 | 0.04 | 0.05 | 0.05 | |
Market cap | 20.53M | 12.07M | 16.1M | 21.96M | 29.86M | |
Enterprise value | 2.95M | -7.2M | 4.02M | 17.39M | 11.44M | |
P/E ratio | -0.66 | -0.42 | -0.48 | -0.67 | -0.54 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.93 | -1.63 | -2.24 | -2.92 | -3.7 | |
PFCF ratio | -2.92 | -1.6 | -2.24 | -2.92 | -3.45 | |
P/B Ratio | 1.61 | 0.78 | 2.2 | -47.02 | -2.24 | |
PTB ratio | 1.61 | 0.78 | 2.2 | -47.02 | -2.24 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.38 | 0.97 | -0.46 | -2.11 | -1.22 | |
EV to operating cash flow | -0.42 | 0.97 | -0.56 | -2.31 | -1.42 | |
EV to free cash flow | -0.42 | 0.96 | -0.56 | -2.31 | -1.32 | |
Earnings yield | -0.38 | -0.6 | -0.53 | -0.37 | -0.46 | |
Free cash flow yield | -0.34 | -0.62 | -0.45 | -0.34 | -0.29 | |
Debt to equity | 0.02 | 0.04 | 0.08 | -1.25 | -0.04 | |
Debt to assets | 0.01 | 0.03 | 0.04 | 0.09 | 0.03 | |
Net debt to EBITDA | 2.26 | 2.6 | 1.39 | 0.55 | 1.96 | |
Current ratio | 2.88 | 3.71 | 1.99 | 0.87 | 1.22 | |
Interest coverage | -1.88K | 1.46K | 70.18 | 0 | 0 | |
Income quality | 0.9 | 1.03 | 0.84 | 0.92 | 0.59 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.02 | 0 | 0 | 0.07 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.21 | -3.09 | 0 | 0 | -14.49 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 7.75 | 7.11 | 3.32 | 0.83 | 5.68 | |
ROIC | -0.59 | -0.44 | -1.01 | -11.82 | 0.77 | |
Return on tangible assets | -0.4 | -0.33 | -0.57 | -1.26 | -0.64 | |
Graham Net | 1.84 | 1.95 | 0.46 | -0.16 | -1.41 | |
Working capital | 12.25M | 15M | 6.89M | -835.66K | 3.64M | |
Tangible asset value | 12.75M | 15.51M | 7.33M | -467K | -13.35M | |
Net current asset value | 12.19M | 14.45M | 6.34M | -1.37M | -14.79M | |
Invested capital | 0.02 | 0.04 | 0.08 | -1.25 | -0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.18M | 4.46M | 4.73M | 6.65M | 7.1M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 10.24K | 3.71K | 11.02K | 10.88K | 12.57K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.61 | -0.47 | -1.15 | 17.6 | 1.03 | |
Capex per share | 0 | -0.02 | 0 | 0 | -0.05 |
CLRB Frequently Asked Questions
What is Cellectar Biosciences, Inc. stock symbol ?
Cellectar Biosciences, Inc. is a US stock , located in Florham park of Nj and trading under the symbol CLRB
What is Cellectar Biosciences, Inc. stock quote today ?
Cellectar Biosciences, Inc. stock price is $3.98 today.
Is Cellectar Biosciences, Inc. stock public?
Yes, Cellectar Biosciences, Inc. is a publicly traded company.